IGBA Appoints Frittelli As 2022 Chair

Vivian Frittelli Sits As Chair Of IGBA For The Second Time

The IGBA has appointed Vivian Frittelli as chair of the organization for 2022, taking over from Sudarshan Jain. It is Frittelli’s second time as chair of IGBA, having taken up the mantle the first time following its 2015 rebrand.

Checkered chair
Frittelli was previously appointed IGBA chair in October 2015 • Source: Alamy

The International Generic and Biosimilar Medicines Association has announced the appointment of Vivian Frittelli, CEO of Generic and Biosimilar Medicines of Southern Africa, as its chair for 2022. Additionally, Jonathan Kimball, vice president of trade and international affairs at the US Association for Accessible Medicines and vice chair of the IGBA International Trade and Intellectual Property Committee, has been appointed as IGBA vice chair.

Frittelli takes over from Sudarshan Jain, secretary general of the Indian Pharmaceutical Alliance, who acted as chair during 2021. (Also see "Who’s Hired

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Leadership

Adalvo And Gedeon Richter Join Forces On Semaglutide

 
• By 

Adalvo and Gedeon Richter have announced a global co-development deal for semaglutide for obesity. Adalvo CEO Anil Okay spoke to Generics Bulletin about the alliance as well as the broader competitive landscape for GLP-1s.

Who’s Hired? Botox Biosimilar Developer Aeon Takes CEO From Rival Revance

 
• By 

Aeon Biopharma has picked up Revance Therapeutics executive Rob Bancroft to serve as its new CEO as it continues to pursue a biosimilar version of Botox. Meanwhile, Coherus has lost its chief commercial officer, as Viatris, Sandoz and Medicines for Ireland have announced new appointments.

Samsung Bioepis Reevaluating Approach To Biosimilars

 

The challenging US biosimilar market remains a persistent problem, leading the biosimilar developer to reconsider how it invests in the future while pushing for changes.

Cardinal Looks Ahead To A New Decade For US Biosimilars

 
• By 

In the wake of a report marking 10 years since the first US biosimilar launch, Cardinal Health’s Dracey Poore speaks to Generics Bulletin about the successes seen so far and the obstacles that must be overcome if the market is to thrive in the decade ahead.

More from Generics Bulletin

Amgen Biosimilars Continue Surge Ahead Of Imminent Denosumab Competition

 
• By 

Thanks to its efficient development pipeline, sales of Amgen’s biosimilars neared $750m for the first three months of the year, offering some comfort as the firm gears up for the loss of exclusivity for its denosumab franchise.

Adalvo And Gedeon Richter Join Forces On Semaglutide

 
• By 

Adalvo and Gedeon Richter have announced a global co-development deal for semaglutide for obesity. Adalvo CEO Anil Okay spoke to Generics Bulletin about the alliance as well as the broader competitive landscape for GLP-1s.

Medicines UK Welcomes NHS England’s Best-Value Biologics Biosimilar Adoption Framework

 
• By 

Reflecting on recent initiatives by NHS England and the MHRA, the newly renamed trade body Medicines UK has welcomed efforts in promoting the use of biosimilars in Britain.